Pfizer Needs The Seagen Deal


  • Pfizer Inc. has been reported as bidding for Seagen Inc., competing with Merck & Co., Inc. for the cancer drug company.
  • Seagen analysts forecast booming sales on FDA approvals of multiple cancer drugs.
  • Seagen shareholders should take the deal and cash out at a premium valuation.
  • Pfizer needs an acquisition with large future revenues to replace lost COVID-19 sales and LOEs.

Hand of people connecting jigsaw puzzles of rising arrow, merger and acquisition, business partnership agreement for success concept, 3d render illustration.

Yossakorn Kaewwannarat

Pfizer Inc. (NYSE:PFE) got a big sales boost from the COVID-19 vaccine, and the end of the pandemic has cut off a big revenue stream. The biotech faces a year with a substantial revenue hit, while the company

Seagen Earnings estimates table

Source: Seeking Alpha

Seagen, Merck and Pfizer PS ratio
Data by YCharts

COVID-19 US vaccines

Source: Pfizer Q4’22 presentation

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

If you’d like to learn more about how to best position yourself in under valued stocks mispriced by the market heading into a 2023 Fed pause, consider joining Out Fox The Street

The service offers model portfolios, daily updates, trade alerts and real-time chat. Sign up now for a risk-free, 2-week trial to start finding the next stock with the potential to generate excessive returns in the next few years without taking on the out sized risk of high flying stocks. 

Leave a Reply

Your email address will not be published. Required fields are marked *